These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 12712480

  • 1. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K.
    Cancer; 2003 May 01; 97(9):2254-61. PubMed ID: 12712480
    [Abstract] [Full Text] [Related]

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M.
    Clin Cancer Res; 2005 Feb 01; 11(3):1119-28. PubMed ID: 15709179
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors.
    Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y, Ohira M, Yamaura A, Osato K, Sakiyama S, Nakagawara A.
    Genes Chromosomes Cancer; 2002 Oct 01; 35(2):170-5. PubMed ID: 12203781
    [Abstract] [Full Text] [Related]

  • 5. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM, Rieske P, Wozniak K, Piaskowski S, Jaskolski DJ, Skowronski W, Golanska E, Sikorska B, Liberski PP.
    Clin Neuropathol; 2006 Oct 01; 25(1):18-24. PubMed ID: 16465770
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
    Gelpi E, Ambros IM, Birner P, Luegmayr A, Drlicek M, Fischer I, Kleinert R, Maier H, Huemer M, Gatterbauer B, Anton J, Rössler K, Budka H, Ambros PF, Hainfellner JA.
    Mod Pathol; 2003 Jul 01; 16(7):708-15. PubMed ID: 12861068
    [Abstract] [Full Text] [Related]

  • 8. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
    Gadji M, Fortin D, Tsanaclis AM, Drouin R.
    Cancer Genet Cytogenet; 2009 Oct 01; 194(1):12-22. PubMed ID: 19737649
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
    Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M.
    Rev Neurol (Paris); 2008 Oct 01; 164(6-7):595-604. PubMed ID: 18565359
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.
    Chin Med J (Engl); 2010 Dec 01; 123(24):3566-73. PubMed ID: 22166632
    [Abstract] [Full Text] [Related]

  • 14. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.
    Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G.
    Brain Pathol; 2004 Apr 01; 14(2):121-30. PubMed ID: 15193024
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF, Afaghi V, Payne CA, Buckland ME, Brewer JM, Biggs MT, Little NS, Wheeler HR, Cook RJ, McDonald KL.
    J Clin Neurosci; 2011 Mar 01; 18(3):329-33. PubMed ID: 21247767
    [Abstract] [Full Text] [Related]

  • 19. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2004 Jul 01; 108(1):49-56. PubMed ID: 15118874
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.